Reported Sunday, MoonLake Announces Phase 3 VELA Program Week 52 Results Showing 67.2% Of Sonelokimab-Treated Patients Achieving HiSCR75 In Moderate-To-Severe Hidradenitis Suppurativa

Loading news article.

Reported Sunday, MoonLake Announces Phase 3 VELA Program Week 52 Results Showing 67.2% Of Sonelokimab-Treated Patients Achieving HiSCR75 In Moderate-To-Severe Hidradenitis Suppurativa | WAPE

Reported Sunday, MoonLake Announces Phase 3 VELA Program Week 52 Results Showing 67.2% Of Sonelokimab-Treated Patients Achieving HiSCR75 In Moderate-To-Severe Hidradenitis Suppurativa

Article summary

Related companies

Comments —